Showing 1571-1580 of 1644 results for "".
- Blood Tests for Alzheimer Disease Advancehttps://practicalneurology.com/news/blood-tests-for-alzheimer-disease-advance/2469338/At the Alzheimer’s Association International Conference (AAIC) 2020, results from several studies reported potential blood test measures for diagnosis and disease monitoring of Alzheimer disease (AD). Most relied on assaying for the presence of various isoforms of phosphorylated tau, p-tau2
- FDA Accepts Supplemental New Drug Application for Pimavanserin for Dementia-Related Psychosis Symptomshttps://practicalneurology.com/news/fda-accepts-supplemental-new-drug-application-for-pimavanserin-for-dementia-related-psychosis-symptoms/2469329/The Food and Drug Administration (FDA) has accepted for filing its supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The sNDA is
- New Indication for Pimavanserin—Dementia Related Psychosis—Submitted to the FDAhttps://practicalneurology.com/news/new-indication-for-pimavanserin-dementia-related-psychosis-submitted-to-the-fda/2469301/A supplemental new drug application (sNDA) for pimavanserin (Nuplazid; Acadia Pharmaseuticals, San Diego, CA) was submitted to the Food and Drug Administration (FDA) for a new indication. Evidence now shows pimavanserin is effective for the treatment of hallucinations and delusions associated wit
- Phase 3 Trial of MSC-NTF Stem Cells for ALS Receives Continued Fundinghttps://practicalneurology.com/news/phase-3-trial-of-msc-ntf-stem-cells-for-als-receives-continued-funding/2469289/The ongoing phase 3 clinical trial of autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, Paramus, NJ) treatment has received funding through a grant. The grant was awarded by the ALS Association and
- Cardiovascular Disease Risk Tripled for American Indians and Alaska Nativeshttps://practicalneurology.com/news/cardiovascular-disease-risk-tripled-for-american-indians-and-alaska-natives/2469279/According to a scientific statement published in the American Heart Association journal Circulation, type 2 diabetes affects American Indians and Alaska natives at approximately 3 times the rate of white Americans and is closely linked to disproportionately high rates of cardiovascular disease.</
- Secondary Prevention Lags for Individuals who Experienced Strokehttps://practicalneurology.com/news/secondary-prevention-lags-for-individuals-who-experienced-stroke/2469262/In a study presented at the American Heart Association's Quality of Care & Outcomes Research Scientific Sessions 2020 (held virtually) individuals who experienced stroke were less likely to receive preventive care for atherosclerotic cardiovascular disease compared with those who had peri
- Long-Term Exposure to Air Pollution and Rate of Cognitive Declinehttps://practicalneurology.com/news/long-term-exposure-to-air-pollution-and-rate-of-cognitive-decline/2469226/In a study published in Neurology researchers found an association of air pollution levels with cognitive impairment and decline in 1 of 2 large groups but not both. Both groups were ethnically and racially diverse and lived in the Northern Manhattan area of New York City. Participant's resid
- FDA Accepts Supplemental NDA for Cannabidiol to Treat Seizures of Tuberous Sclerosis Complexhttps://practicalneurology.com/news/fda-accepts-supplemental-nda-for-cannabidiol-to-treat-seizures-of-tuberous-sclerosis-complex/2469212/The US Food and Drug Administration (FDA) has accepted for filing, with priority review, a recently submitted supplemental new drug application (sNDA) for the use of cannabidiol (Epidiolex, GW Pharmaceuticals, Carlsbad, CA) CV to treat seizures associated with tuberous sclerosis complex (TSC). Th
- AHA Promotes Secondary Stroke Prevention as Crucial During COVID-19 Pandemichttps://practicalneurology.com/news/aha-promotes-secondary-stroke-prevention-as-crucial-during-covid-19-pandemic/2469197/As hospitals, healthcare systems, and healthcare providers strive to reduce the spread of coronavirus, the American Heart Association (AHA) offers tips for heart attack and stroke survivors for secondary prevention during this difficult time. Based on current information about the
- Recombinant Factor Xa for Anticoagulant Reversal Lowers Mortality Rateshttps://practicalneurology.com/news/recombinant-factor-xa-for-anticoagulant-reversal-lowers-mortality-rates/2469191/New data reinforces the value of recombinant factor Xa (Andexxa, Portola Pharmaceuticals, South San Francisco, CA). Use of recombinant factor Xa to reverse anticoagulation with rivaroxaban, apixaban, or warfarin was associated with a lower rate of in-hospital and 30-day mortality compared with 4-